Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity

Hypoxia, or gradients of hypoxia, occurs in most growing solid tumors and may result in pleotropic effects contributing significantly to tumor aggressiveness and therapy resistance. Indeed, the generated hypoxic stress has a strong impact on tumor cell biology. For example, it may contribute to increasing tumor heterogeneity, help cells gain new functional properties and/or select certain cell subpopulations, facilitating the emergence of therapeutic resistant cancer clones, including cancer stem cells coincident with tumor relapse and progression. It controls tumor immunogenicity, immune plasticity, and promotes the differentiation and expansion of immune-suppressive stromal cells. In this context, manipulation of the hypoxic microenvironment may be considered for preventing or reverting the malignant transformation. Here, we review the current knowledge on how hypoxic stress in tumor microenvironments impacts on tumor heterogeneity, plasticity and resistance, with a special interest in the impact on immune resistance and tumor immunogenicity.

[1]  S. Liang,et al.  Preclinical evidence of the enhanced effectiveness of combined rapamycin and AICAR in reducing kidney cancer , 2018, Molecular oncology.

[2]  Weijun Peng,et al.  Jianpi Jiedu decoction, a traditional Chinese medicine formula, inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1α/VEGF pathway. , 2018, Journal of ethnopharmacology.

[3]  W. Liu,et al.  Two-photon fluorescent probe for detection of nitroreductase and hypoxia-specific microenvironment of cancer stem cell. , 2018, Analytica Chimica Acta.

[4]  Juan Ma,et al.  Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death‐ligand 1 expression by reducing hypoxia‐inducible factor‐1&agr; and STAT3 , 2018, Pharmacological research.

[5]  H. Ling,et al.  Signalling mechanism(s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[6]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[7]  Enrique J. deAndrés-Galiana,et al.  NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. , 2018, Cancer research.

[8]  I. Petersen,et al.  Stem cell transcription factor SOX2 in synovial sarcoma and other soft tissue tumors. , 2018, Pathology, research and practice.

[9]  Qiang Yu,et al.  Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer , 2018, Proceedings of the National Academy of Sciences.

[10]  G. Semenza,et al.  Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment. , 2018, Cancer research.

[11]  Jung-Hwan Yoon,et al.  Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro. , 2018, Oncology letters.

[12]  Jiaqi Tang,et al.  Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression , 2018, Cancers.

[13]  S. Chevillard,et al.  Breast cancer stem cell-like cells generated during TGFβ-induced EMT are radioresistant , 2018, Oncotarget.

[14]  S. Bhattacharyya,et al.  Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells , 2018, Cancer Cell International.

[15]  B. Vojtesek,et al.  STAT3, stem cells, cancer stem cells and p63 , 2018, Cellular & Molecular Biology Letters.

[16]  G. Kaur,et al.  Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges , 2018, Current Treatment Options in Oncology.

[17]  C. Zwieb,et al.  A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers , 2018, Clinical Cancer Research.

[18]  Inna Kuperstein,et al.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. , 2018, Cancer cell.

[19]  T. S. Ramasamy,et al.  Cancer stem cells as key drivers of tumour progression , 2018, Journal of Biomedical Science.

[20]  M. de la Guardia,et al.  Modulating tumor hypoxia by nanomedicine for effective cancer therapy , 2018, Journal of cellular physiology.

[21]  B. Coyle,et al.  A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells , 2018, Cellular Oncology.

[22]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[23]  Yongping Song,et al.  TGFβ1-induced down-regulation of microRNA-138 contributes to epithelial-mesenchymal transition in primary lung cancer cells. , 2018, Biochemical and biophysical research communications.

[24]  C. Zahnow,et al.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells , 2018, Proceedings of the National Academy of Sciences.

[25]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[26]  T. Gajewski,et al.  Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.

[27]  V. Keshamouni,et al.  Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer , 2018, The Journal of clinical investigation.

[28]  Jeffrey H. Chuang,et al.  Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma , 2017, Oncotarget.

[29]  W. Blalock,et al.  MiRNA-210: A Current Overview. , 2017, Anticancer research.

[30]  F. Nicolantonio,et al.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth , 2017, Nature.

[31]  P. Davis,et al.  Subcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: a review , 2017, Journal of Clinical Pathology.

[32]  Tiara Bunga Mayang Permata,et al.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.

[33]  S. Terry,et al.  Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity , 2017, Front. Immunol..

[34]  J. Bergh,et al.  An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression , 2017, Cancer cell.

[35]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[36]  S. Terry,et al.  Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3 , 2017, Oncotarget.

[37]  M. Simon,et al.  Oxygen availability and metabolic reprogramming in cancer , 2017, The Journal of Biological Chemistry.

[38]  B. Groner,et al.  Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.

[39]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[40]  B. Goh,et al.  Do STAT3 inhibitors have potential in the future for cancer therapy? , 2017, Expert opinion on investigational drugs.

[41]  F. Azuaje,et al.  CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT , 2017, Oncoimmunology.

[42]  J. Thiery,et al.  New insights into the role of EMT in tumor immune escape , 2017, Molecular oncology.

[43]  V. Gopalan,et al.  The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer. , 2017, Clinical colorectal cancer.

[44]  T. Cloughesy,et al.  Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma , 2017, Neuro-oncology.

[45]  Q. Dong,et al.  Clinical and prognostic significance of HIF-1α overexpression in oral squamous cell carcinoma: a meta-analysis , 2017, World Journal of Surgical Oncology.

[46]  Benjamin D. Greenbaum,et al.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.

[47]  R. Weinberg,et al.  Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.

[48]  E. Grande,et al.  Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. , 2017, Critical reviews in oncology/hematology.

[49]  Matthew D Disney,et al.  Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. , 2017, Journal of the American Chemical Society.

[50]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[51]  M. Rudin,et al.  Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells , 2017, Current Biology.

[52]  T. Tan,et al.  Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity , 2017, Oncoimmunology.

[53]  M. Konopleva,et al.  Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy , 2017, Clinical Cancer Research.

[54]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[55]  T. Tan,et al.  The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200 , 2017, Oncoimmunology.

[56]  O. Cuvillier The therapeutic potential of HIF-2 antagonism in renal cell carcinoma , 2017, Translational andrology and urology.

[57]  Amanda B. Keener Shapeshifters in cancer: How some tumor cells change phenotype to evade therapy , 2016, Nature Medicine.

[58]  Hyejin Cho,et al.  On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models , 2016, Nature.

[59]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[60]  A. Moustakas,et al.  Transforming growth factor β as regulator of cancer stemness and metastasis , 2016, British Journal of Cancer.

[61]  S. Påhlman,et al.  Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.

[62]  M. Ferrer,et al.  Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer , 2016, Clinical Cancer Research.

[63]  C. Sarkar,et al.  HIF-2α mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis. , 2016, The international journal of biochemistry & cell biology.

[64]  E. Rankin,et al.  Hypoxic control of metastasis , 2016, Science.

[65]  A. Carnero,et al.  The hypoxic microenvironment: A determinant of cancer stem cell evolution , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

[66]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[67]  C. Pan,et al.  REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling , 2016, Oncotarget.

[68]  Chuanzhao Zhang,et al.  Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA , 2016, Proceedings of the National Academy of Sciences.

[69]  G. Salzano,et al.  Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors , 2016, Oncotarget.

[70]  E. Ben-Jacob,et al.  Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome , 2016, Proceedings of the National Academy of Sciences.

[71]  Qi Zhang,et al.  Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. , 2016, Cancer research.

[72]  S. Dedhar,et al.  Targeting hypoxic response for cancer therapy , 2016, Oncotarget.

[73]  Yong-Chen Lu,et al.  Cancer immunotherapy targeting neoantigens. , 2016, Seminars in immunology.

[74]  S. Terry,et al.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. , 2015, American journal of physiology. Cell physiology.

[75]  G. Semenza,et al.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells , 2015, Proceedings of the National Academy of Sciences.

[76]  G. Salzano,et al.  Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells , 2015, Oncotarget.

[77]  P. Glazer,et al.  Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. , 2015, DNA repair.

[78]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[79]  C. Elly,et al.  E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity. , 2015, Immunity.

[80]  Meiyan Wu,et al.  HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer , 2015, PloS one.

[81]  Yang Liu,et al.  Hypoxia-inducible factors in cancer stem cells and inflammation. , 2015, Trends in pharmacological sciences.

[82]  Y. Murayama,et al.  Emerging roles of hypoxia‐inducible factors and reactive oxygen species in cancer and pluripotent stem cells , 2015, The Kaohsiung journal of medical sciences.

[83]  Sha Cao,et al.  Cancer may be a pathway to cell survival under persistent hypoxia and elevated ROS: A model for solid‐cancer initiation and early development , 2015, International journal of cancer.

[84]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[85]  Akio Ohta,et al.  Immunological mechanisms of the antitumor effects of supplemental oxygenation , 2015, Science Translational Medicine.

[86]  P. Validire,et al.  CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.

[87]  Lu Ding,et al.  miR-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell. , 2015, International journal of clinical and experimental medicine.

[88]  M. Chilosi,et al.  Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells , 2015, British Journal of Cancer.

[89]  H. Beltran,et al.  CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities , 2015, OncoTarget.

[90]  G. Calin,et al.  Hypoxia Mediated Downregulation of miRNA Biogenesis Promotes Tumor Progression , 2014, Nature Communications.

[91]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[92]  Paul C. Boutros,et al.  Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER , 2014, Nature Communications.

[93]  R. Weinberg,et al.  Tackling the cancer stem cells — what challenges do they pose? , 2014, Nature Reviews Drug Discovery.

[94]  T. Tan,et al.  Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression , 2014, Oncogene.

[95]  H. Yao,et al.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. , 2014, Cancer cell.

[96]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[97]  K. Tsang,et al.  WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. , 2014, Cancer research.

[98]  M. Pawlus,et al.  STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells , 2014, Oncogene.

[99]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[100]  M. Bernaudin,et al.  Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. , 2014, Investigative ophthalmology & visual science.

[101]  Kou-Juey Wu,et al.  Epigenetic regulation of hypoxia‐responsive gene expression: Focusing on chromatin and DNA modifications , 2014, International journal of cancer.

[102]  Gwendoline Gros,et al.  Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF-β1 , 2013, The Journal of Immunology.

[103]  Paola Chiarugi,et al.  Microenvironment and tumor cell plasticity: an easy way out. , 2013, Cancer letters.

[104]  N. Inoue,et al.  Hypoxia-Induced Reactive Oxygen Species Cause Chromosomal Abnormalities in Endothelial Cells in the Tumor Microenvironment , 2013, PloS one.

[105]  R. Bristow,et al.  Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.

[106]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[107]  P. Xie,et al.  M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway , 2013, Laboratory Investigation.

[108]  A. G. de Herreros,et al.  Epithelial–Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor , 2013, The Journal of Immunology.

[109]  T. Tan,et al.  Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. , 2013, Cancer research.

[110]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[111]  A. Tsimberidou,et al.  Anti-vascular endothelial growth factor therapy in the era of personalized medicine , 2013, Cancer Chemotherapy and Pharmacology.

[112]  Kou-Juey Wu,et al.  Hypoxia-regulated target genes implicated in tumor metastasis , 2012, Journal of Biomedical Science.

[113]  T. Hagemann,et al.  The tumor microenvironment at a glance , 2012, Journal of Cell Science.

[114]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[115]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[116]  E. Clambey,et al.  Hypoxia-inducible factor-1 alpha–dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa , 2012, Proceedings of the National Academy of Sciences.

[117]  P. Romero,et al.  Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. , 2012, Cancer research.

[118]  G. Semenza,et al.  Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.

[119]  G. Semenza,et al.  Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.

[120]  D. Tang,et al.  Understanding cancer stem cell heterogeneity and plasticity , 2012, Cell Research.

[121]  I. Melero,et al.  Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer , 2011, Clinical Cancer Research.

[122]  N. Marchionni,et al.  NOTCH SIGNALLING MODULATES HYPOXIA-INDUCED NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CANCER CELLS , 2012 .

[123]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[124]  Y. Matsumoto,et al.  Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia, and reoxygenation. , 2011, Journal of radiation research.

[125]  Xiuping Liu,et al.  The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. , 2011, Cancer research.

[126]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[127]  P. Puigserver,et al.  A Hypoxia-Induced Positive Feedback Loop Promotes Hypoxia-Inducible Factor 1α Stability through miR-210 Suppression of Glycerol-3-Phosphate Dehydrogenase 1-Like , 2011, Molecular and Cellular Biology.

[128]  W. Bodmer,et al.  Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells , 2011, Proceedings of the National Academy of Sciences.

[129]  M. Post,et al.  Mouse Snail Is a Target Gene for HIF , 2011, Molecular Cancer Research.

[130]  C. Marsh,et al.  Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes. , 2011, Blood.

[131]  T. Padhya,et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.

[132]  W. Wong,et al.  Hypoxia-inducible factors and the response to hypoxic stress. , 2010, Molecular cell.

[133]  R. Cardiff,et al.  Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. , 2010, Cancer cell.

[134]  Nadira Trncic,et al.  Hypoxia/Reoxygenation-Induced Mutations in Mammalian Cells Detected by the Flow Cytometry Mutation Assay and Characterized by Mutant Spectrum , 2010, Radiation research.

[135]  G. Semenza Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[136]  A. Harris,et al.  Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. , 2010, Cancer research.

[137]  M. Wei,et al.  New strategies for cancer gene therapy: Progress and opportunities , 2010, Clinical and experimental pharmacology & physiology.

[138]  K. Eckardt,et al.  The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia , 2009, The Journal of Biological Chemistry.

[139]  A. Arai,et al.  Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. , 2009, The American journal of pathology.

[140]  M. Simon,et al.  Hypoxia-inducible factors in stem cells and cancer , 2009, Journal of cellular and molecular medicine.

[141]  Huafeng Zhang,et al.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.

[142]  J. Arbeit,et al.  Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. , 2009, Cancer research.

[143]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[144]  A. Sica,et al.  Divergent effects of hypoxia on dendritic cell functions. , 2008, Blood.

[145]  Tae-You Kim,et al.  STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination , 2008, Experimental & Molecular Medicine.

[146]  R. Roberts,et al.  Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. , 2008, Stem cells and development.

[147]  U. Lendahl,et al.  Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.

[148]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[149]  Kou-Juey Wu,et al.  Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.

[150]  D. Kirkpatrick,et al.  Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α , 2008, Molecular Cancer Therapeutics.

[151]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[152]  V. Lazar,et al.  αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis , 2007, The Journal of experimental medicine.

[153]  M. Charbonneau,et al.  Transforming Growth Factor β1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression* , 2006, Journal of Biological Chemistry.

[154]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[155]  Brian Keith,et al.  HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. , 2006, Genes & development.

[156]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[157]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[158]  Jung Weon Lee,et al.  The FASEB Journal express article 10.1096/fj.04-3099fje. Published online May 26, 2005. ©2005 FASEB , 2022 .

[159]  W. Linehan,et al.  Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. , 2005, Cancer research.

[160]  P. Glazer,et al.  Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. , 2005, Mutation research.

[161]  K. Blackwell,et al.  Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? , 2004, The oncologist.

[162]  Paul Lizardi,et al.  Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells , 2004, Molecular and Cellular Biology.

[163]  J. Zavadil,et al.  Integration of TGF‐β/Smad and Jagged1/Notch signalling in epithelial‐to‐mesenchymal transition , 2004 .

[164]  G. Paine-Murrieta,et al.  Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.

[165]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[166]  P. Glazer,et al.  Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells , 2003, Molecular and Cellular Biology.

[167]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[168]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[169]  P. Glazer,et al.  Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.

[170]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[171]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[172]  V. Gopalan,et al.  The clinical and biological roles of transforming growth factor beta in colon cancer stem cells: A systematic review. , 2018, European journal of cell biology.

[173]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[174]  M. Simon,et al.  HIF-2 (cid:1) regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth , 2006 .

[175]  M. Dewhirst,et al.  Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. , 2001, Cancer research.